RIGEL PHARMACEUTICALS INC (RIGL)

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 155 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The firm's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).

Company Info

RIGEL PHARMACEUTICALS INC

611 Gateway Boulevard, Suite 900

South San Francisco CALIFORNIA 94080

P: 16506241100

CEO: Raul R. Rodriguez

Employees: 155

Website: https://www.rigel.com/